{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:26:50Z","timestamp":1791170810451,"version":"4.1.0"},"reference-count":106,"publisher":"JLE","issue":"7","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.nephro.2010.12.008","type":"journal-article","created":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T09:37:14Z","timestamp":1296121034000},"page":"566-581","source":"Crossref","is-referenced-by-count":6,"title":["Traitements immunosuppresseurs\u00a0: m\u00e9canismes d\u2019action et utilisation clinique"],"prefix":"10.1684","volume":"7","author":[{"given":"\u00c9ric","family":"Thervet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sberro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Canaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Anglicheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Snanoudj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Mamzer-Bruneel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Legendre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2010.12.008_bib0005","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"issue":"Suppl. 3","key":"10.1016\/j.nephro.2010.12.008_bib0010","doi-asserted-by":"crossref","first-page":"iii8","DOI":"10.1093\/ndt\/gfh1007","article-title":"Causes of death and mortality risk factors","volume":"19","author":"Alonso","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1034\/j.1600-6143.2003.00176.x","article-title":"Evolution of endpoints for renal transplant outcome","volume":"3","author":"Hariharan","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0020","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra011295","article-title":"Strategies to improve long-term outcomes after renal transplantation","volume":"346","author":"Pascual","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0025","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1074-7613(04)00116-5","article-title":"The roles of the new negative T cell costimulatory pathways in regulating autoimmunity","volume":"20","author":"Khoury","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.nephro.2010.12.008_bib0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"10.1016\/j.nephro.2010.12.008_bib0040","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","article-title":"FTY720: sphingosine 1-phosphate receptor-1\u00a0in the control of lymphocyte egress and endothelial barrier function","volume":"4","author":"Brinkmann","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0045","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids-new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-6143.2007.02084.x","article-title":"Trials and tribulations of steroid withdrawal after kidney transplantation","volume":"8","author":"Meier-Kriesche","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0055","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1749-6632.1993.tb17138.x","article-title":"Calcineurin is a key signaling enzyme in T lymphocyte activation and the target of the immunosuppressive drugs cyclosporin A and FK506","volume":"696","author":"Clipstone","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nephro.2010.12.008_bib0060","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34\u00a0recipients of cadaveric organs: 32\u00a0kidneys, 2\u00a0pancreases, and 2\u00a0livers","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2010.12.008_bib0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(85)90477-5","article-title":"Cyclosporin in cadaveric renal transplantation: 3-year follow-up of a European multicentre trial","volume":"2","author":"Calne","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2010.12.008_bib0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/01.TP.0000128167.60172.CC","article-title":"Natural history, risk factors, and impact of subclinical rejection in kidney transplantation","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0075","first-page":"S63","article-title":"The differential diagnosis between rejection and cyclosporine toxicity","volume":"52","author":"Mihatsch","year":"1995","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nephro.2010.12.008_bib0080","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ki.1997.328","article-title":"Cyclosporine and the renin-angiotensin axis","volume":"52","author":"Lee","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2010.12.008_bib0085","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/oxfordjournals.ndt.a027761","article-title":"Cyclosporin A-associated hypertension--pathomechanisms and clinical consequences","volume":"12","author":"Haas","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"4\u00a0Pt 2","key":"10.1016\/j.nephro.2010.12.008_bib0090","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.HYP.25.4.764","article-title":"Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells","volume":"25","author":"Marumo","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.nephro.2010.12.008_bib0095","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2362.1991.tb01395.x","article-title":"Cyclosporin-A-induced lipid peroxidation in human liver microsomes and its influence on cytochrome P-450","volume":"21","author":"Inselmann","year":"1991","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.nephro.2010.12.008_bib0100","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/00007890-198811000-00017","article-title":"The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients","volume":"46","author":"Kasiske","year":"1988","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007890-199907150-00011","article-title":"Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation","volume":"68","author":"Mahalati","year":"1999","journal-title":"Transplantation"},{"issue":"Suppl. 9","key":"10.1016\/j.nephro.2010.12.008_bib0110","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1097\/00007890-200205151-00003","article-title":"Patient management by Neoral C(2) monitoring: an international consensus statement","volume":"73","author":"Levy","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0115","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1432-2277.2005.00151.x","article-title":"Use of Neoral C monitoring: a European consensus","volume":"18","author":"Nashan","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.nephro.2010.12.008_bib0120","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1097\/00007890-199612270-00009","article-title":"A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group","volume":"62","author":"Keown","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0125","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1097\/01.tp.0000268306.41196.2c","article-title":"The clinical benefits of cyclosporine C2-level monitoring: a systematic review","volume":"83","author":"Knight","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.healun.2006.03.020","article-title":"Cyclosporine C2\u00a0target levels and acute cellular rejection after lung transplantation","volume":"25","author":"Glanville","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0135","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.nephro.2010.12.008_bib0140","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0145","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1600-6143.2007.01749.x","article-title":"Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus","volume":"7","author":"Vincenti","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0150","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.tp.0000181195.67084.94","article-title":"Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients","volume":"80","author":"Tricot","year":"2005","journal-title":"Transplantation"},{"issue":"Suppl. 2","key":"10.1016\/j.nephro.2010.12.008_bib0155","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.2215\/CJN.02770707","article-title":"BK virus nephritis after renal transplantation","volume":"3","author":"Dall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0160","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/ndt\/17.8.1487","article-title":"C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients","volume":"17","author":"J\u00f8rgensen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0165","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/j.1523-1755.2005.00352.x","article-title":"AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients","volume":"67","author":"Scholten","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2010.12.008_bib0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14622416.6.1.37","article-title":"Cytochrome P450 3A polymorphisms and immunosuppressive drugs","volume":"6","author":"Thervet","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.nephro.2010.12.008_bib0175","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5\u00a0expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.nephro.2010.12.008_bib0180","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","article-title":"Impact of cytochrome p450 3A5\u00a0genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0185","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1600-6143.2004.00435.x","article-title":"The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation","volume":"4","author":"MacPhee","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0190","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/j.1600-6143.2006.01518.x","article-title":"CYP3A5\u00a0and ABCB1\u00a0polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study","volume":"6","author":"Haufroid","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0195","first-page":"269","article-title":"Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results","volume":"1","author":"Thervet","year":"2006","journal-title":"Int J Nanomedicine"},{"issue":"Suppl. 3","key":"10.1016\/j.nephro.2010.12.008_bib0200","doi-asserted-by":"crossref","first-page":"37S","DOI":"10.1016\/S0041-1345(03)00353-1","article-title":"Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation","volume":"35","author":"Kahan","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2010.12.008_bib0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1432-2277.2004.00052.x","article-title":"Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48\u00a0months after transplantation","volume":"18","author":"Oberbauer","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.nephro.2010.12.008_bib0215","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0220","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0225","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0230","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/01.TP.0000157868.95359.30","article-title":"Impact of sirolimus on early graft function after deceased-donor kidney transplantation","volume":"79","author":"McTaggart","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0235","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nephro.2006.04.006","article-title":"N\u00e9phrotoxicit\u00e9 du sirolimus\u00a0: donn\u00e9es cliniques et exp\u00e9rimentales","volume":"2","author":"Pallet","year":"2006","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.nephro.2010.12.008_bib0240","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.transproceed.2006.03.013","article-title":"Lymphocele after renal transplantation: the influence of the immunosuppressive therapy","volume":"38","author":"Tondolo","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2010.12.008_bib0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.7326\/0003-4819-144-7-200604040-00009","article-title":"Brief communication: sirolimus-associated pneumonitis: 24\u00a0cases in renal transplant recipients","volume":"144","author":"Champion","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0250","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1399-0012.2007.00669.x","article-title":"Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients","volume":"21","author":"Haririan","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0255","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00007890-199702150-00010","article-title":"Maintenance therapy with triple versus double immunosuppressive regimen in renal transplantation: a meta-analysis","volume":"63","author":"Kunz","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0260","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1681\/ASN.2006101153","article-title":"Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial","volume":"18","author":"Remuzzi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0265","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/00007890-199606270-00019","article-title":"Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis","volume":"61","author":"Pol","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0270","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1365-2036.2005.02703.x","article-title":"Observations on the use of allopurinol in combination with azathioprine or mercaptopurine","volume":"22","author":"Duley","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.nephro.2010.12.008_bib0275","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00007890-199710150-00027","article-title":"Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout","volume":"64","author":"Jacobs","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0280","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1097\/00007890-200004150-00057","article-title":"Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients","volume":"69","author":"Sebbag","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0285","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/j.1600-6143.2004.00575.x","article-title":"Thiopurine S-methyltransferase genotype predicts azathioprine-induced myelotoxicity in kidney transplant recipients","volume":"4","author":"Formea","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0290","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1681\/ASN.V121170","article-title":"Long-term results of TMPT activity monitoring in azathioprine-treated renal allograft recipients","volume":"12","author":"Thervet","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0295","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O\u2019Donovan","year":"2005","journal-title":"Science"},{"issue":"Suppl. 2","key":"10.1016\/j.nephro.2010.12.008_bib0300","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","article-title":"Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection","volume":"80","author":"Allison","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00007890-199701150-00008","article-title":"Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Group","volume":"63","author":"Halloran","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0310","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1111\/j.1600-6143.2006.01320.x","article-title":"Severe diarrhea in renal transplant patients: results of the DIDACT study","volume":"6","author":"Maes","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0315","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","article-title":"Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study","volume":"4","author":"Budde","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0320","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.5.6.1333","article-title":"Review of the immunosuppressant enteric-coated mycophenolate sodium","volume":"5","author":"Budde","year":"2004","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nephro.2010.12.008_bib0325","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.1600-6143.2003.00337.x","article-title":"Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients","volume":"4","author":"Salvadori","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0330","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2215\/CJN.03861106","article-title":"Therapeutic drug monitoring of mycophenolic acid","volume":"2","author":"Shaw","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0335","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1345\/aph.1D063","article-title":"Enteric-coated mycophenolate sodium","volume":"37","author":"Gabardi","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nephro.2010.12.008_bib0340","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.transproceed.2004.12.186","article-title":"Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil","volume":"37","author":"Tedesco-Silva","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nephro.2010.12.008_bib0345","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.ftd.0000199358.80013.bd","article-title":"Therapeutic drug monitoring of mycophenolate mofetil in transplantation","volume":"28","author":"Van Gelder","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.nephro.2010.12.008_bib0350","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2165\/00003088-200544080-00005","article-title":"A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil","volume":"44","author":"Pr\u00e9maud","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.nephro.2010.12.008_bib0355","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-199907270-00018","article-title":"A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation","volume":"68","author":"Van Gelder","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0360","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1600-6143.2007.01983.x","article-title":"Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation","volume":"7","author":"Le Meur","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0365","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-6143.2005.01152.x","article-title":"Concurrent antiviral and immunosuppressive activities of leflunomide in vivo","volume":"6","author":"Chong","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0370","first-page":"2453","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity. 1975","volume":"174","author":"Kohler","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0375","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1126\/science.3086976","article-title":"The human immune response to the OKT3\u00a0monoclonal antibody is oligoclonal","volume":"232","author":"Chatenoud","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.nephro.2010.12.008_bib0380","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00007890-199602270-00011","article-title":"The IgE humoral response in OKT3-treated patients. Incidence and fine specificity","volume":"61","author":"Abramowicz","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0385","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00007890-199605270-00009","article-title":"Detection of IGA anti-OKT3\u00a0antibodies in OKT3-treated transplant recipients","volume":"61","author":"McIntyre","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0390","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4049\/jimmunol.137.3.830","article-title":"Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3","volume":"137","author":"Chatenoud","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0395","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/eji.1830140803","article-title":"Unusually restricted anti-isotype human immune response to OKT3\u00a0monoclonal antibody","volume":"14","author":"Baudrihaye","year":"1984","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0400","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199209033271018","article-title":"Anaphylactic shock after retreatment with OKT3\u00a0monoclonal antibody","volume":"327","author":"Abramowicz","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0405","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00007890-198810000-00011","article-title":"Effectiveness of a second course of OKT3\u00a0monoclonal anti-T cell antibody for treatment of renal allograft rejection","volume":"46","author":"Norman","year":"1988","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0410","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007890-199201000-00016","article-title":"Prediction of successful allograft rejection retreatment with OKT3","volume":"53","author":"Legendre","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0415","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/00007890-198606000-00013","article-title":"Prophylactic use of OKT3\u00a0monoclonal antibody in cadaver kidney recipients. Utilization of OKT3\u00a0as the sole immunosuppressive agent","volume":"41","author":"Vigeral","year":"1986","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0420","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1681\/ASN.V981521","article-title":"Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3\u00a0antibody response in kidney transplant recipients","volume":"9","author":"Broeders","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0425","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/00007890-198904000-00008","article-title":"Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3\u00a0monoclonal antibody in kidney transplant recipients","volume":"47","author":"Abramowicz","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0430","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00007890-199004000-00009","article-title":"In vivo cell activation following OKT3\u00a0administration. Systemic cytokine release and modulation by corticosteroids","volume":"49","author":"Chatenoud","year":"1990","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0435","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0923-2494(98)80001-1","article-title":"In vivo and in vitro production of monoclonal antibodies: current possibilities and future perspectives. Introduction","volume":"149","author":"de Geus","year":"1998","journal-title":"Res Immunol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0440","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/00007890-199710150-00012","article-title":"A pilot trial of recombinant human interleukin-10\u00a0in kidney transplant recipients receiving OKT3\u00a0induction therapy","volume":"64","author":"Wissing","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0445","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/eji.1830171112","article-title":"Induction of T cell proliferation with anti-CD3\u00a0switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems","volume":"17","author":"Van Lier","year":"1987","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.nephro.2010.12.008_bib0450","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0455","first-page":"301","article-title":"Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31\u00a0cadaveric renal allograft recipients","volume":"101","author":"Calne","year":"2000","journal-title":"Nippon Geka Gakkai Zasshi"},{"key":"10.1016\/j.nephro.2010.12.008_bib0460","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2010.12.008_bib0465","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0470","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0475","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-199901150-00019","article-title":"Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group","volume":"67","author":"Nashan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0480","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/00007890-200009150-00013","article-title":"Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group","volume":"70","author":"Thistlethwaite","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0485","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0490","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0495","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1600-6143.2005.00749.x","article-title":"Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties","volume":"5","author":"Larsen","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nephro.2010.12.008_bib0500","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/01.TP.0000054835.58014.C2","article-title":"Prevention of kidney allograft rejection using anti-CD40\u00a0and anti-CD86\u00a0in primates","volume":"75","author":"Haanstra","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.nephro.2010.12.008_bib0505","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0510","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0272-6386(99)70414-2","article-title":"Incidence and long-term cost of steroid-related side effects after renal transplantation","volume":"33","author":"Veenstra","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nephro.2010.12.008_bib0515","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1681\/ASN.V8111771","article-title":"Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis","volume":"8","author":"Szczech","year":"1997","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.nephro.2010.12.008_bib0520","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004756.pub3","article-title":"Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients","author":"Webster","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nephro.2010.12.008_bib0525","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1056\/NEJMoa071074","article-title":"HLA-mismatched renal transplantation without maintenance immunosuppression","volume":"358","author":"Kawai","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2010.12.008_bib0530","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa074191","article-title":"Tolerance and chimerism after renal and hematopoietic-cell transplantation","volume":"358","author":"Scandling","year":"2008","journal-title":"N Engl J Med"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725510002609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725510002609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2010.12.008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T15:00:43Z","timestamp":1741186843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725510002609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1769725510002609"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2010.12.008","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}